ProBioGen invests €20m in mammalian manufacturing expansion

Published: 10-Sep-2014
Manufacturing Research & Development Pharmaceutical

Announcement coincides with company's twentieth anniversary


ProBioGen, a specialist in the development and manufacturing of complex therapeutic glycoproteins and viral vaccines, is to planning to double its workforce and invest €20m at its site in Berlin, Germany.

'With an investment of around €20m we will strengthen our market position, add two additional disposable 1000L bioreactors and, within the next two years, will double our staff from currently 75 highly skilled and dedicated employees,' said CEO Dr Wieland Wolf.

ProBioGen is developing novel biotechnological processes for the production of biopharmaceutical drug substances to treat serious diseases on behalf of pharmaceutical and biotech companies. The service spectrum ranges from cell line and process development up to GMP contract manufacturing.

In addition, the Berlin scientists develop innovative technologies to improve biotechnologically active substances and have created an extensive portfolio of proprietary rights for optimised biopharmaceutical manufacturing. Licences have recently been granted to a number of global pharmaceutical companies, including Boehringer Ingelheim and Novartis.

  • Companies:
  • ProBioGen AG
See more

You may also like

Manufacturing

ProBioGen and DIOSynVax partner to manufacture multivalent vaccine for hemorrhagic fever

Read more
The novel vaccine targets HF diseases caused by Ebola, Marburg, and Lassa viruses

Trending Articles

  1. TekniPlex Healthcare to showcase expanded capacity and sustainability solutions at Pharmapack Company highlights EU-based advancements in injection blow molding, multilayer blown films, and sustainable blister packaging
  2. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms
  5. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

ProBioGen and DIOSynVax partner to manufacture multivalent vaccine for hemorrhagic fever

The novel vaccine targets HF diseases caused by Ebola, Marburg, and Lassa viruses
Manufacturing

ProBioGen enters technology collaboration with Boehringer Ingelheim

It contributes to Boehringer Ingelheim's goal of using cutting-edge technologies across the whole biopharmaceutical value chain
Manufacturing

ProBioGen and Thermo Fisher Scientific team up on cell platform

The new kit uses Thermo Fisher's ExpiCHO-S cell line and a new powerful media platform specifically developed for it
Manufacturing

ProBioGen and City of Hope announce commercial licence for manufacturing

The agreement will allow City of Hope to manufacture its MVA-based CMV vaccine using ProBioGen’s platform
Manufacturing

ProBioGen chooses NextPoint for GMP manufacturing of antibody

NextPoint has been selected to fast track CMC development and manufacturing of this unique antibody that targets a novel immune checkpoint axis offering promise for hard-to-treat cancers
Manufacturing

AstraZeneca licenses GlymaxX tech for drug discovery

GlymaxX technology, developed by ProBioGen, prevents the addition of the sugar "fucose" to the N-linked antibody carbohydrate part by antibody producing cells
Manufacturing

Innovent licenses ProBioGen’s GlymaxX technology

Under this license agreement, Innovent receives non-exclusive rights to use the afucosylation technology GlymaxX for multiple candidates in its pipeline
Subscribe now